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Objective To estimate the prevalence of benign prostatic
hyperplasia (BPH) in the community, and study the
influence of BPH definition, age and response bias on
prevalence rates.
Subjects and methods A community-based longitudinal
study of 3924 men aged 50–75 years was conducted
in a Dutch municipality (Krimpen) near Rotterdam.
Data from those responding were collected using self-
administered questionnaires, and during visits to the
health centre and outpatient clinic of the urology
department. The questionnaires included symptom
scores on general well being (Inventory of Subjective
Health, ISH) and lower urinary tract symptoms
(International Prostate Symptom Score, IPSS). A
short version of the questionnaire (including the
IPSS and ISH) was sent to a random sample of those
not responding. All subjects participating fully under-
went a physical examination, uroflowmetry, trans-
rectal ultrasonometry of the prostate and had their
prostate specific antigen level measured. Age-specific
prevalence rates of BPH were estimated using different
definitions, based on one or more of symptom severity,
prostate volume and maximum flow rate. The
influence of response bias was estimated using the
questionnaires.
Results The response rate was 50% (full participants). Of
those not responding, 55% completed a short version
of the questionnaire (partial participants). Compared
with full participants, partial participants had a lower
IPSS and slightly lower ISH. The prevalence rates of
clinical BPH in the study population was 9–20% (95%
confidence interval, 8–11% to 22–27%) depending on
the definition used. After adjusting for nonresponse
bias, the age-group specific prevalences for 5-year age
strata were 1.1–1.8 times lower for all BPH definitions
used.
Conclusions The prevalence rates of clinical BPH depend
largely on the definition used and increase strongly
with age. The effect of age is stronger when more
variables are included in the definition. Adjustment for
response bias results in substantially lower prevalence
rates.
Keywords Prevalence, BPH, response bias, age
Introduction
Clinical BPH is a common diagnosis in older men, but the
reported prevalence of this condition varies considerably.
Garraway et al. [1] reported a prevalence of 25% in men
aged 40–79 years, whereas Bosch et al. [2] found rates of
4–19% using different definitions for BPH. The study of
the natural history of BPH has been hampered by three
major problems. First, there is a lack of consensus about
the definition of BPH. Most definitions are based on the
concept of Hald [3], which combines LUTS, prostate
volume and objective proof of difficult micturition. To
describe these properties various studies have used
different variables and different threshold values of
these variables. Second, as most community studies
have not considered nonresponse bias, it is not known
whether they are truly representative. One preliminary
study on potential nonresponse bias, the Olmsted County
Study (OCS), suggested that the response might have
been affected by concern about urological disease [4].
Third, there is a paucity of data on the natural history of
BPH based on longitudinal community studies.
To gain information on male urogenital tract dysfunc-
tion, and the prevalence and incidence of clinical BPH
(and its determinants) in men aged over 50 years, a
prospective community-based study was designed, i.e.
the Krimpen study of male urogenital tract problems and
general health status. The aim of this study was toAccepted for publication 4 January 2000
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investigate the prevalence rates of BPH in the community
using various definitions, and to study the influence of
age and nonresponse bias on these values.
Subjects and methods
From all general practices in Krimpen aan den IJssel (a
commuter suburb near Rotterdam, with < 28 000
inhabitants) the names and addresses of all 3924
registered men aged 50–75 years were obtained (refer-
ence date June 1995). In the Netherlands, almost
every person is registered with a general practice [5].
Recruitment took place between August 1995 and
January 1998; the reasons for exclusion are given in
Table 1. Men previously operated for BPH (n=64) were
not excluded but were analysed separately. In all cases
the GP decided whether or not the patient could enter the
first phase of the study; the GPs’ reasons for exclusion
were checked by the investigators in the electronic
medical records.
Figure 1 presents an overview of the study scheme. All
3398 enrolled men were invited by mail to complete a
self-administered questionnaire and to attend the health
centre. During the recruitment period about 40 men
were invited weekly. Because the recruitment period was
lengthy, 152 men had passed the age of 75 years but
were nevertheless enrolled; in all, 1688 men agreed to
participate (a response rate of 50%).
Procedures
The questionnaire included: two inventories on general
well-being, i.e. the Sickness Impact Profile [6,7] and a 13-
item version of the Inventory of Subjective Health (ISH)
[8]; the IPSS [9]; the BPH impact score [10]; and ICSsex
questionnaire [11]. In addition, information on marital
status, educational level, treatment for chronic diseases,
smoking and drinking habits was collected.
At the health centre, two study physicians checked the
questionnaires and completed these with data on the
present use of medication using the Anatomical
Therapeutical Chemical classification [12]. Urine was
analysed using a dipstick test, mainly to exclude lower
urinary tract infection, and the subjects’ blood pressure,
height and body weight measured.
The second part of the study was conducted at the
urology outpatient department of the University Hospital
Rotterdam. Before attendance, participants were asked to
complete a 3-day voiding diary. The following measure-
ments were obtained: DRE; TRUS performed with a 7-
MHz multiplanar sector-scanning probe to measure
volumes, using the planimetric technique of volume
measurement [13]; uroflowmetry, recording of peak flow
rate (Qmax) and other variables with a flowmeter (Dantec
Urodyn 1000, Copenhagen, Denmark); postvoid residual
urine volume, determined by transabdominal ultra-
sonometry; and the serum PSA level (Tandem-R
method, Hybritech, San Diego, CA).
The following protocol was used to detect prostatic
carcinoma. Prostate biopsies were taken; (i) from all men
with PSA values of >10 ng/mL; (ii) from men with a PSA
level of 2–10 ng/mL if there were abnormal findings on
DRE or TRUS (i.e. suspect for carcinoma); and (iii), in
men with a PSA level of 1–2 ng/mL only if the DRE was
abnormal. No biopsies were taken to confirm the
histopathological diagnosis of BPH. In all, 57 men had
prostatic cancer and they were analysed separately; eight
of these had been operated previously for BPH.
Partial participants and complete nonresponders
A random sample (500), stratified proportional to the
number of nonresponders per general practice, was taken
from the list of nonresponders to evaluate whether the
responders were representative. These nonresponders
were invited to complete a short mailed questionnaire
which included the ISH, IPSS, and questions on
treatment for chronic diseases, marital status, educa-
tional level, smoking and drinking habits, and current
use of medication. Questionnaires were sent in October
1997 and had to be returned within 6 weeks. Of those
not responding, 261 returned the questionnaires
(response rate 55%) and became ‘partial participants’.
All men who completed the second part of the study
and who were not diagnosed with prostatic cancer and
had no previous operation for BPH (n=1553) will be
re-evaluated after 2 and 4 years.
Table 1 Reasons for exclusion from the first phase of the study
Reason Number of men (%)
Radical prostatectomy 011 (5)
Known prostatic or bladder cancer 034 (14)
Under treatment by urologist 014 (6)
Neurogenic bladder disease 026 (11)
Inability to complete questionnaire
(dementia, mental retardation,
language problem)
032 (14)
Inability to attend health centre 007 (7)
Negative advice by patient’s GP 105 (45)
Cardiac disease 023 (10)
Pulmonary disease 014 (6)
Malignancy 027 (11)
Not specified 041 (17)
Unknown 006 (3)
Total 235 (100)
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Prevalence of BPH and estimation of response bias
The age-specific prevalence of BPH was estimated using
different definitions, i.e. the definition used by Garraway
et al. [1] and three different definitions reported to be the
most valid by Bosch et al. [2]. The variables used in these
definitions were the IPSS, Qmax and prostate volume.
To adjust for response bias, age-group specific
prevalences of men with an IPSS of >7 were estimated
as the weighted average of the prevalence in the full-
participant group and the estimated prevalence in the
nonresponder group. It was assumed that the IPSS of the
partial participants represented the IPSS of all nonre-
sponders, and that the other variables used in the
definitions of BPH are independent of the IPSS and
equally distributed among full and partial participants.
If the total nonresponders had either lower or higher
prevalences than the partial participants (in contrast to
the assumption) the adjusted prevalences in those
with an IPSS of >7 in the population would differ. A
sensitivity analysis was conducted to evaluate the effect
of variation in the IPSS in the total nonresponder group,
ranging from a best-case to a worst-case scenario, on the
adjusted prevalence rates of men with an IPSS of >7 in
the total population.
Statistical analysis
Full and partial participants were compared for items on
the short questionnaire using multivariate logistic
regression, the t-test, chi-square test and the Mantel–
Haenszel test, as applicable. The relation between age
and prevalence rates of BPH and its determinants was
tested using univariate regression (because of assump-
tions of normality, dependent variables were trans-
formed), chi-square test and the Mantel–Haenszel test.
Inhabitants of Krimpen aan den IJssel
n = –  28 000
Men aged 50 to 75 years
n = 3924
Included
n = 3398
Moved/deceased on moment of invitation
n = 291
Excluded
n = 235
Responders
n = 1688
Non-responders
n = 1710
No information in phase I
n = 27
Completed phase I*
n = 1661
Random sample
n = 500
Moved/deceased
n = 28
Partial participants
(return of questionnaire)
n = 261
No return of questionnaire
n = 211
Withdrawn
n = 22
Phase II†
n = 1666‡
Men with carcinoma of prostate or
previous prostate operation for BPH (n = 113)
men in follow-up study (n = 1553)
Fig. 1. Flow chart of the study: *self-administered questionnaire; {see text — 1592 men completed phase II, 69 men visited the clinic without a
completed voiding diary and five men completed the diary but did not visit the clinic.
Table 2 Age groups and age-group specific response rates
Age, years (n)* No. of included men (%) No. of responders Response rate (%)
Response rate in
random sample (%)
50–54 (859) 0788 (91) 0356 45.2 50.4
55–59 (891) 0813 (91) 0432 53.1 57.4
60–64 (798) 0720 (90) 0398 55.3 55.8
65–69 (711) 0622 (88) 0318 51.1 54.0
70–78 (659) 0452 (68) 0184 40.7 57.5
Total (3924) 3398 (87){ 1688 49.7 55.3
*Age on date of invitation, n = number of men in age group; { age calculation of three men missing.
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Correlation between these variables was estimated by
means of Spearman’s rho. The study was approved by the
Medical Ethical Committee of the Erasmus University
Rotterdam and the University Hospital Rotterdam. All
participants gave written informed consent.
Results
Age groups of responders and nonresponders, and age-
group specific response rates, are given in Table 2. There
was a slight under-representation of men aged 50–
55 years and of men aged >70 years, and a slight over-
representation of those aged 60–65 years. The mean age
of the partial participants did not differ from that of the
total nonresponders (62.7 years, SD 7.4 years, compared
with 62.3 years, SD 7.6 years; P=0.6). Age-group specific
response rates in the random sample are also given in
Table 2.
Table 3 shows the characteristics of the included men;
full participants were slightly younger than the partial
participants.
Multivariate logistic regression, adjusted for age,
shows that full participants had less treatment for
chronic diseases (odds ratio, OR, 0.60, P<0.001),
Table 3 Characteristics of the men included in the study
Characteristic Full participants Partial participants P{
Number 1688 261
Mean (SD) age (years)* 0061.2 (6.7) 062.7 (7.4) <0.001{
Percentage:
Marital status 000.06
Married 0091.4 0088.1
Unmarried 0002.3 0003.6
Cohabitation 0003.1 0002.4
Divorced 0001.0 0002.8
Widower 0002.2 0003.2
Educational level 000.43
No education/Primary school 0013 0016
Secondary education 0061 0063
University 0026 0021
Smoking habits 000.24
Never smoked 0019 0020
Stopped smoking 0050 0057
Current smoker 0031 0023
Drinking habits 000.57
No alcohol 0023 0027
Average 1–2 units per day 0059 0056
Average >2 units per day 0018 0017
Under treatment for chronic diseases
Diabetes mellitus 0003.4 0005.3 000.11
Hypertension 0015.9 00018.7 000.25
Chronic obstructive pulmonary disease 0004.5 0004.6 000.96
Parkinson’s disease 0000.1 0000.8 000.03
Cardiac disease 0006.2 0008.8 000.11
Chronic UTI 0000.8 0001.5 000.28
Liver disease 0000.7 0000 000.29
One or more of the above 0025 0032 <0.01
Prostatic cancer in 1st degree family member 0091 0094 000.11
ISH questionnaire
Mean (SD) 0002.02 (2.34) 0001.55 (2.15) <0.003{
IPSS (%) <0.001
No symptoms 0010 0019
Minor 0065 0066
Moderate 0022 0014
Severe 0003 0001
IPSS QoL <0.001
Delighted to mostly satisfied 0083 0092
Mixed, to terrible 0017 0008
*Age on date of invitation; { chi-square test or { t-test.
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marginally higher mini-ISH scores (OR 1.08, P=0.06),
and a higher percentage had an IPSS of >7 (OR 1.70,
P<0.02). The effect of IPSS quality of life (QoL) question
in the multivariate logistic regression was similar to the
effect of an IPSS of >7 when separately included in the
model. When both IPSS and QoL were included in the
model, the effect of these variables was much weaker,
because of their strong correlation (Pearson’s correlation
coefficient = 0.68, P<0.001).
Prevalence of BPH
Table 4 gives the median score and 25–75th percentiles
of the variables used to estimate the prevalence of BPH
according to different definitions. The IPSS and prostate
volume increased with age, and Qmax decreased with
age (P<0.001 for all three). The variables are weakly
correlated: IPSS vs prostate volume, Spearman’s
rho=0.13; IPSS vs Qmax, rho=x0.20; prostate
volume vs Qmax, rho=x0.13 (P<0.001 for all).
Prevalence rates of BPH according to different defini-
tions and with adjustment for response bias are also
given in Table 4. Different definitions of BPH resulted in
substantially different prevalence rates. Definitions taking
all three variables (IPSS, prostate volume and Qmax) into
consideration showed a larger effect of age on the
prevalence than definitions including only one or two
variables. All (corrected and uncorrected) prevalence
rates showed a significant increase with age. In three of
the five definitions there was a small decrease in
prevalence in those aged 70–78 years after adjusting
for response bias. Adjusting for response bias resulted in
lower prevalence rates for all definitions and across all
age groups. In estimating the adjusted prevalences of
those with an IPSS of >7, it was assumed that the partial
participants represented the nonresponder group. The
effect of the sensitivity analysis on the adjusted
prevalence rates in men with an IPSS of >7 is also
given in Table 4.
Discussion
Considering the effort required from the responders and
the number of invasive tests performed, the present 50%
response rate was remarkably high. It was higher than
that of two other Dutch studies on the prevalence of BPH;
Bosch et al. [14] reported an age-group specific response
rate of 33–36% and Wolfs et al. [15] reported a 39%
overall response rate. In Scotland, Garraway et al. [1]
reported an overall response rate of 65%, whereas the
OCS reported 48% [16]. In the OCS, home visits were
made to complete the questionnaire and uroflowmetry;
only a quarter of the responding men (randomly
sampled) was invited for further evaluation at a urology
clinic [16]. Garraway et al. [1] performed TRUS only in
men with signs and symptoms of prostatic dysfunction
(symptom scores and Qmax).
In the present study, all the objective measures were
obtained in all full participants, allowing an estimate of
community-based age-specific reference values for pros-
tate size, uroflowmetry and PSA level. Furthermore, the
prevalence of BPH can then be estimated using different
definitions. In this community-based study the preva-
lence rates of BPH were 9–25% in men aged 50–78 years.
These rates may be an underestimate because men
previously operated for BPH were not included in the
calculation; however, this latter group represents only
< 4% of the responders.
The full participants were comparable with the partial
participants for educational and marital status, smoking
and drinking habits. Full participants were slightly
younger and had been treated less often treated for one
or more chronic diseases, but had higher ISH scores.
Partial participants were more often ‘delighted to mostly
satisfied’ about their current voiding symptoms.
Although different methods were used to evaluate
nonresponse in the OCS, the present results were
comparable with those in the OCS [4]; however,
prevalence rates of BPH from the OCS were not adjusted
for this bias.
In the present study, the GP decided whether to
propose a patient for enrolment; this may be considered
as a potential limitation to the study. In retrospect, that
almost 15% of the excluded men had died within one
month to 2 years after exclusion suggests that the GPs’
decision on eligibility was valid.
The prevalence of men with an IPSS of >7 was lower
in those not responding. When estimating the prevalence
rates of BPH using the IPSS as part of the definition it is
important to adjust for this bias. In the present study, this
adjustment resulted in substantially lower prevalence
rates, particularly in the youngest and oldest strata. The
adjusted prevalence rates of IPSS >7 would be over-
estimated if the partial participants had a higher IPSS
than the total nonresponders. However, this overestimate
is not large (3.7%) even assuming that none of the total
nonresponders had an IPSS of >7. In the OCS study [4],
the total nonresponders had lower prevalence rates for
BPH and other urological diagnoses than had partial
responders. Therefore, the worst case scenario presented
here is unlikely. It seems to be more realistic to assume
that the true prevalence of men with an IPSS of >7 will
be 16–20%.
In conclusion, the prevalence of BPH depends largely
on age and the definition used. The age effect is stronger
when more variables are included in the definition of
BPH. Future prevalence studies and models using
prevalence rates of BPH should use various definitions,
670 M.H. BLANKER et al.
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and adjust for nonresponse bias with subdivision into age
strata.
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